Experimental Heart Disease Drug Pelacarsen Fails to Prevent Heart Attacks and Strokes
Pelacarsen Clinical Trial Failure Rattles Pharmaceutical Outlook The pharmaceutical industry faced a sharp market reality check this Saturday as an experimental heart disease drug, pelacarsen, failed to deliver on its primary clinical endpoints. Developed by Novartis and Ionis Pharmaceuticals, the drug was positioned as a potential breakthrough for patients with elevated lipoprotein(a), or Lp(a)—a genetic … Read more